Latest Breaking News On - Williamm scholl - Page 1 : vimarsana.com

Werewolf Therapeutics Appoints Michael Atkins, M D , to its Board of Directors

04.01.2024 - WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE therapeutics .

United statesWilliamm schollEllen lubmanMichael atkinsMelanoma research alliance medical advisory panelSociety for the immunotherapy of cancerVerge scientific communicationsProfessor at harvard medical schoolAdvisory councilCancer centerWerewolf therapeutics incCompany contactAcademy of immunooncologyWerewolf boardDeputy directorGeorgetown lombardi comprehensive cancer center

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Michael atkinsJosh rappaportEllen lubmanDanielj hicklinWilliamm schollExchange commissionJazz pharmaceuticalsCompany or werewolf nasdaqDepartment of oncology at georgetown universitySociety for immunotherapy of cancerCompany contactScientific communicationsWerewolf therapeutics incTherapeutics reports third quarterProvides businessChief executive officer

Werewolf Therapeutics Reports Third Quarter 2023 Financial

– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of.

Michael atkinsEllen lubmanJosh rappaportWilliamm schollDanielj hicklinJazz pharmaceuticalsSociety for immunotherapy of cancerExchange commissionDepartment of oncology at georgetown universityWerewolf therapeutics incCompany or werewolf nasdaqCompany contactScientific communicationsChief executive officerAnnual meetingVice chair

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

WATERTOWN, Mass., Sept. 11, 2023 Werewolf Therapeutics, Inc. , an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate.

Josh rappaportMichaelb atkinsWilliamm schollMichael atkinsEllen lubmanDivision of hematology oncologyAdvisory committeeLombardi immunotherapy initiativeWerewolf therapeutics incBeth israel deaconess medical centerGlobenewswire incScientific advisory councilGeorgetown universityCompany or werewolf nasdaqHarvard medical schoolScientific communications

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Michaelb atkinsEllen lubmanJosh rappaportMichael atkinsWilliamm schollGeorgetown lombardi comprehensive cancer centerLombardi immunotherapy initiativeAdvisory committeeOncology at medstar georgetown university hospitalDepartment of oncologyDivision of hematology oncologyTufts medical centerProfessor at harvard medical schoolBeth israel deaconess medical centerWerewolf therapeutics incCompany or werewolf nasdaq